J&J vaccine rollout to resume in Europe with safety warning |
Clinical News
eMediNexus Coverage from: 
J&J vaccine rollout to resume in Europe with safety warning

0 Read Comments                

Johnson & Johnson has stated that it will resume the rollout of its COVID-19 vaccine in Europe after the medical regulator mentioned that the benefits of the vaccine outweigh the risk of very rare, potentially lethal blood clots.

The European Medicines Agency (EMA) has recommended that a warning regarding rare blood clots with low platelet count be added to the vaccine’s product label and stated that the benefits of the single-dose vaccine outweigh its risks.

J&J vaccine rollout was temporarily paused by U.S. regulators last week following reports of rare brain blood clots along with low blood platelet count in six women, which made the company delay its rollout in Europe… (Reuters, April 20, 2021)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now